We describe the protocolised use of 23.4% hypertonic saline solution (HTS) for intracranial hypertension in the context of traumatic brain injury in the paediatric population. This study represents the largest published data on the use of 23.4% HTS in the paediatric population. In this retrospective cohort, we focus on the efficacy, biochemical and metabolic consequences of 23.4% HTS administration in a Level 1 paediatric trauma centre. Mortality in the first seven days was 6% (2/32) with a mean intensive care unit length-of-stay of ten days (range 2 to 25, standard deviation [SD] 6). All-cause hospital mortality was 6%, with no deaths after the seven-day study period. Mean intracranial pressure (ICP) response to HTS was 10 mmHg (range 1 to 30, SD 8). For biochemistry data, the mean highest daily serum sodium was 148 mmol/l (139 to 161, SD 6), mean highest serum chloride was 115 mmol/l (range 101 to 132, SD 8) with matched mean serum base excess of -1.5 mmol/l (range 2 to -8, SD 3) and mean peak serum creatinine was 73 mmol/l (range 32 to 104, SD 32). Glasgow outcome scores of >3 (independent function) were achieved in 74% of patients. We describe the use of 23.4% HTS, demonstrating it to be a practical and efficacious method of delivering osmoles and may be advantageous in minimising total fluid volume. Thus, the bolus versus infusion debate may best be served via combining both approaches. We suggest investigation into the stabilisation of intracranial pressure with highly HTS and maintenance with a less hypertonic infusion is warranted. In this way, volume could potentially be minimised with rapid control of intracranial pressure and reduced secondary brain injury.
The purpose of this study is to describe the use of hypertonic saline solution (HTS) for intracranial hypertension in the context of traumatic brain injury (TBI) in the paediatric population. We sought to particularly focus on the efficacy and biochemical and metabolic consequences of 23.4% HTS administration in this population.
Trauma is the leading cause of death in children after the first year of life in the developed world. TBI accounts for a major fraction of these deaths 1 . Severe brain injury results in cerebral oedema which leads to elevated intracranial pressure (ICP), the net result being reduced cerebral perfusion pressure and secondary ischaemic injury. Appropriate and timely treatment of elevated ICP improves cerebral perfusion aimed at reducing this secondary ischaemic insult.
The use of hyperosmolar agents to reduce ICP has been known for over 90 years 2 , yet it continues to suffer from a paucity of evidence in paediatric practice. From the initial use of fluid and sodium restriction in the mid-20th century, there has been a move towards the hyperosmolar euvolaemic state. The cornerstones of osmotherapy have been mannitol and HTS, with the latter gaining wider acceptance in the critical care setting 3, 4 . There has been a notable trend in recent data demonstrating the preferential use of HTS over mannitol 5 . A recent meta-analysis by Lazaridis concluded that in adults 23.4% HTS was a lowvolume, safe and efficient method of reducing ICP 6 . Repeat doses of HTS have also been demonstrated to be efficacious and safe in the adult population 7, 8 . Both mannitol and HTS have favourable, well-defined osmotic and rheologic properties. However, HTS theoretically aids in stabilising neural membranes 9, 10 and may act as an anti-inflammatory agent reducing cerebral blood volume via contraction of vessels in the pia mater 11, 12 . Both agents have also been demonstrated to improve cerebral blood-flow to areas hypoperfused in TBI 13 . HTS has also been demonstrated to stimulate atrial natriuretic peptide. However, atrial natriuretic peptide has only been demonstrated to reduce ICP in a rodent model via intraventricular administration 14 . Suggestions that a higher plasma osmolality may be better tolerated than that observed with mannitol are as yet unsubstantiated.
The best formulation of HTS and its method of administration is undefined, but the evidence for HTS is strengthening 3, 4 . There is considerable variation in concentration and mode of administration methods between institutions 15 . In our unit during the study period, bolus administration of 23.4% HTS (0.5 ml/kg infused over ten minutes) was used as the standard hyperosmolar therapy. This concentration represents the upper limits for hypertonic solutions used clinically and it has been demonstrated to be safe and efficacious in the adult population [7] [8] [9] [10] [11] [12] [13] [16] [17] [18] [19] . A recent case study of two paediatric patients receiving 23.4% HTS demonstrated acute lowering of ICP with increased cerebral perfusion pressure and this was sustained over a period of two hours 20 . The recent release of the paediatric TBI guidelines published in Paediatric Critical Care Medicine 21 has prompted us to review our use of HTS in our institution and report on its efficacy as well as the biochemical and metabolic consequences of its use. To our knowledge, this represents the largest published study on the use of 23.4% HTS in paediatric literature.
Methods
A retrospective cohort review was conducted of patients admitted to an Australian paediatric trauma centre intensive care unit (ICU) who met the following criteria:
• Age <18 years at time of ICU admission, • TBI listed as primary diagnosis on admission, • ICP monitor placed, • ICP >20 mmHg for >5 minutes not responding to stepwise head injury management protocol and • 23.4% HTS administered for the purpose of controlling ICP.
The study period was from January 2003 until December 2011 inclusive and reflects the duration of the last published guidance on paediatric TBI 22 in an attempt to standardise care over the period. Ethical approval for this study was given by the Hunter New England Human Research Ethics Committee, however due to the study being classified as "a quality improvement exercise/an audit" it was deemed to not need a formal approval number.
During the study period, 1844 paediatric patients were admitted to the ICU and, of these, 155 were identified with head injury as their primary diagnosis. Of 155, 32 children met the criteria. Data was reviewed for the first seven days of the ICU admission as well as for all-cause hospital mortality.
Standardised therapy
During the study period, patients with TBI were treated incrementally in accordance with the institutional paediatric TBI guideline. All patients received head elevation of 20 to 30°, sedation with benzodiazepines and opiates, ventilation to target low normal PaCO 2 (targeting end-tidal CO 2 of 30 to 35 mmHg) and PaO 2 >100 mmHg.
Patients with ICP >20 mmHg for >5 minutes were first administered bolus benzodiazepine and opiate followed by non-depolarising muscle relaxant. Normothermia was maintained (if core temperature >37.5°C with persistent ICP >20 mmHg, cooling with topical ice packing to 36.5°C when cooling would cease. Therapeutic hypothermia was not utilised). Inotropic support was instituted to maintain cerebral perfusion pressure of >40 mmHg for children under 11 years and >60 mmHg for children 11 years and over. Where the ICP remained elevated at >20 mmHg for >5 minutes, in spite of the aforementioned therapy, 23.5% HTS was administered.
Hyperosmolar therapy
Osmotherapy was utilised under this institutional guideline in instances where the standard unit protocol was not successful at lowering ICP to <20 mmHg. Contraindications to HTS were a plasma sodium >155 mmol/l and the absence of central venous access. Osmolality was not measured unless mannitol had been used. A dose of 0.5 ml/ kg of 23.4% HTS (equal to a sodium load of 2 mmol/kg) was given up to a 30 ml maximum.
Other therapies
Thiopentone infusion was used as an adjunct in refractory cases at the discretion of the consultant intensivist. Propofol was used at the discretion of the duty intensivist but not in children <12 years old.
Measurements
Demographic data recorded included age at time of admission, gender, weight, first Glasgow Coma Scale score recorded, Injury Severity Score (ISS), ICP on insertion and highest ICP recorded.
Intervention data included type of ICP monitoring, use of mannitol therapy, total episodes of ICP requiring HTS, daily dose of HTS and total dose of HTS in the first seven days. Where decompressive craniectomy occurred, this was also recorded.
Outcome data included mortality (in the first seven days and all-cause hospital mortality), ICP response (Formula 1), mean ICP response (Formula 2), daily peak serum sodium, creatinine, chloride and matched serum base excess and osmolality. Glasgow Coma Scale score on ICU discharge and Glasgow Outcome Score (GOS) were also recorded 23 . The records were examined daily for adverse events associated with HTS therapy including severe hypernatraemia, central demyelinolysis, subarachnoid haemorrhage, renal impairment, acute pulmonary oedema, natriuresis and high urinary water losses 24, 25 . To determine renal function, we used age-corrected creatinine ranges 26 . We used the definition of acute renal failure as described by the modified paediatric RIFLE criteria (Risk, Injury, Failure, Loss, End-stage renal disease) 27 . Creatinine clearance was estimated using the Shull's formula using both weight and age 28 .
Results
Of the 155 children identified with TBI admitted to the ICU, 41 (26%) had an ICP monitor placed; of these 41 children, 34 (83%) required HTS to maintain ICP according to the unit protocol. Two patients with injuries secondary to hanging were excluded as it was considered that this represented hypoxic brain injury rather than traumatic brain injury. Of the 32 patients in the study group, 18 (56%) had parenchymal monitors placed and 14 (44%) received external ventricular drains primarily. Two patients who initially received parenchymal monitoring had subsequent external ventricular drains placed.
The demographic profile is described in Table 1 . The most common mechanism was motor vehicle accident (21 [62%] ) and males accounted for 63% of patients. The two deaths occurred on days two and five. None of the 30 remaining patients died during the remainder of their ICU or hospital admission.
ICP data was complete in all but one patient. In this instance they were excluded from the ICP data but biochemical data was collected. The mean ICP reduction after HTS load was 10.2 mmHg, but variable (standard deviation 8 mmHg). The mean response was sustained but reduced in subsequent doses as demonstrated in Figure 1 .
The initial serum sodium levels were mean 139 mmol/l with only one patient falling outside of the reference range of with a sodium of 150 mmol/l (135 to 145 mmol/l). There was no correlation between HTS and peak sodium or increase in serum. The highest serum sodium level in the first seven days was 161 mmol/l in a 17-year-old female who had ICP refractory to HTS and mannitol (given when sodium >155 mmol/l) and died on day five.
HTS was administered on a single day or consecutive days in 23 patients. There were eight patients who, after an initial dose of HTS were HTS-free for ≥24 hours and subsequently required a second exposure to HTS. All eight were noted to have had their serum sodium fall to ≤140 mmol/l (mean 136 mmol/l) at the time that this second exposure to HTS was required.
Peak chloride concentrations did not correlate with HTS load. The base excess (BE), which was recorded at the time of peak serum chloride, demonstrated no correlation, with R 2 0.0048 (Figure2).
ICP Response to HTS = (PreHTS ICP) -(ICP 60 min PostHTS)
Formula 1: Formula to calculate response to HTS for each dose. HTShypertonic saline solution, ICP=intracranial pressure.
Formula 2: Formula to calculate mean response to HTS where n=number of episodes requiring HTS in the first seven days of admission. HTS=hypertonic saline solution, ICP=intracranial pressure. Mannitol was received by ten patients and only two of these occurrences were in the ICU, with the majority occurring in the pre-hospital or emergency department setting. Two patients aged 17 and 14 years old received mannitol due to serum sodium >155 mmol/l.
No patient developed acute renal failure by the paediatric RIFLE criteria definition and no patient received renal replacement therapy. Mean creatinine clearance was calculated as 89 ml/minute/1.73 m 2 (range 64 to 144, standard deviation 16). The peak creatinine was frequently noted to be at time of admission, occurring on day one in 21 of 32 patients (66%). The mean age-corrected peak creatinine was noted to be 9% above the upper reference range. There was no correlation between age-corrected creatinine level and peak sodium concentration or sodium chloride load (R 2 0.049 and 0.0006 respectively).
Glasgow Coma Scale score on discharge from ICU and GOS are described in Table 2 . The GOS was 5 (normal life activities) in 48%, 4 (disabled but independent) in 26%, 3 (conscious but severely disabled) in 19% and 1 (deceased) in 6%. No patients were in a persistent vegetative state (GOS 2). One patient was lost to follow-up due to moving outside of the referral area.
Decompressive craniectomy was undertaken in two cases. The first, a 15-year-old male, after the unit protocol including HTS failed to relieve ICP. The second, a 16-year-old female who developed severe vasogenic oedema on day three. Both patients survived until hospital discharge with GOS of 5 and 3 respectively.
One patient received 3% HTS infusion for cerebral salt wasting syndrome. There were no reported episodes of demyelination, acute subarachnoid haemorrhage, acute pulmonary oedema or extravasation injury.
Discussion

Efficacy of 23.4% HTS in lowering ICP
Our results indicate that the majority of paediatric patients respond to 23.4% HTS administered via bolus technique with a mean of 10.2 mmHg reduction in ICP (Figure 1 ). This is in keeping with recently published work by Lewandowski et al that described a 10.1 mmHg decrement in an adult population 7 . It must be noted that this result is in combination with a standardised TBI protocol. Our study agrees with the recently published case series of two patients by Nakagawa et al 20 . They demonstrated a mean response to 23.4% HTS in the paediatric population of 7.9 mmHg and 12.8 mmHg, respectively. The efficacy in adults suggested by Lazaridis of a 50% reduction in ICP would seem to be similar in the paediatric population we have observed 6 . The use of 23.4% HTS thus produces a reduction in ICP with a relatively modest increase in net fluid balance as compared with infusion or bolus methods used in previous studies. The infusion method used by Simma et al required 1950 ml/m 2 / day, Peterson et al used between 11 and 27 ml/kg/day and Fisher used one-off volumes of 6.5 to 10 ml/kg [29] [30] [31] . Using 23.4% HTS the maximal volume required was 6.5 ml/kg over the seven-day period with a mean of only 2 ml/kg. This may offer a benefit to the clinician wishing to avoid volume loading in patients who are often overloaded in their extracellular fluid volume.
Although 23.4% HTS may be a useful method to achieve a rapid osmolar gradient between blood and the central nervous system, sustaining this gradient was a potential problem identified. We noted a failure to maintain serum sodium levels in one-third of our patients, associated with subsequent need for HTS to control ICP when the sodium level fell below 140 mmol/l in eight patients needing a return to hyperosmolar therapy after initial stabilisation (defined as >24 hours free of hyperosmolar therapy). 
Biochemical response
Peak sodium concentrations were lower in our study than those previously published. The recent guidelines surmised that there was no evidence of sufficient quality to recommend mannitol or HTS solutions of greater than 3% 21 . The level II evidence for 3% HTS was based on two studies. The first by Fisher et al comparing bolus 3% HTS and 0.9% saline in 18 children over a period of two hours, the second by Simma et al comparing infusions of 1.7% HTS and Ringer's lactate solution in 35 patients 29, 30 . Both studies used much larger doses of sodium chloride than our study, which used 117 mg/kg bolus doses with a range of 107 to 251 mg/kg/ day (Fisher 195 to 300 mg/kg bolus, Simma 352 to 808 mg/ kg/day). As a result, it is not surprising that the peak serum sodium concentrations were lower in our study.
Our observations support the maintenance of serum sodium ≥140 mmol/l, as when serum sodium fell below this level, ICP again became difficult to control via nonosmotherapeutic mechanisms. We observed this in eight patients who had previously had stable ICPs for 24 hours.
Chloride loading is another potential side-effect of HTS therapy with its potential effect on acid-base balance via the strong ion difference. There was no correlation of sodium chloride load and peak serum chloride (R 2 =0.09). There was no association with metabolic acidosis (as measured by BE) when compared to HTS load (R 2 =0.005). There was a downward trend in BE (reduction in BE) when compared to peak chloride concentration however, there was no correlation (Figure 2 ).
There were no occasions where osmolarity was noted to be in excess of the recommended ranges as described by the various head injury societies. This fits with the relatively low instance of mannitol therapy and lower overall mg/kg dose of sodium chloride when compared to infusion methods. All but two patients receiving mannitol had their blood osmolarity measured with a mean of 305.7 mOsm/l (standard deviation 15, range 281 to 333 mOsm/l). The patient with the lowest osmolarity of 281 mOsm/l was suspected of having cerebral salt wasting syndrome and received an infusion of 3% HTS.
The history of acute renal failure and HTS administration has origins in two papers. Khanna described two patients with renal failure in the setting of sepsis and multi-organ dysfunction and Dominguez described three cases where serum creatinine was increased by two-to three-fold when sodium was maintained above 160 mmol/l 24, 25 . There were no instances of acute renal failure in our cohort. Figure 3 demonstrates age-corrected peak serum creatinine within the first seven days. We compared this peak HTS load and peak plasma sodium concentration with age-corrected creatinine. Both HTS load and peak sodium concentration failed to correlate with peak creatinine levels. The largest elevation in peak creatinine was a 50% increase above the age-corrected upper limit representing a creatinine clearance of 64 ml/minute/1.73m 2 in a 14-year-old male. Only one dose of HTS was administered to this patient and this occurred the day after this peak in creatinine result and hence, was not causal.
Nakagawa demonstrated efficacy in two patients with TBI failing to respond to standard 3% HTS therapy and did not observe any of the potential side-effects of HTS 20 . Our study did not demonstrate any episodes of previously suggested complications such as acute renal impairment, subarachnoid haemorrhage, acute pulmonary oedema, demyelination or extravasation injuries. This low side-effect profile would seem to reflect the experience with adult patients and 23.4% HTS [6] [7] [8] .
Outcome data
GOS data demonstrated that 74% of patients would likely return to or achieve an independent existence (i.e. GOS 4 and 5). Previous studies have suggested that at least 40% would not live independently 29 . This lower rate of dependency may represent the poor ability of the GOS to detect more subtle changes associated with behaviours and memory 32 . The GOS data was obtained over a wide time range (3 to 12 months) due to the variable follow-up periods for severe and less severe injuries on discharge (i.e. more severely injured patients were followed up in a shorter time). This wide interval may skew the data towards a higher (improved) GOS, given time for recovery may have been possible.
Limitations
Our population was small, however it represents the largest study of paediatric TBI and the use of 23.4% HTS. The mean ISS of 19 in our cohort was also lower than that in Peterson et al (ISS 33.6) and Fisher et al (ISS 28.3) and this was due to the high incidence of isolated head -40 Creatinine % above upper limit injury 29, 31 . This was also reflected in the mortality rate being lower in our study than that of Peterson et al (6% versus 15%) as well as fewer patients being classified as dependent (GOS less than 4) than anticipated. The ICP data was impeded by the lack of resolution of the data with only halfhourly to hourly ICP measurements. In regards to potential advantages of reduced volume loading, we must point out that we have not accounted for other maintenance fluid, bolus fluids that patients received for cardiovascular purposes or inotropic support that may distort this perceived clinical advantage.
Conclusion
In the absence of large-scale randomised studies of osmotic agents in paediatric head injury, we have become reliant on expert advice from professional bodies to inform our practice. We have demonstrated that the use of 23.4% HTS is a practical and efficacious method of delivering osmoles for the purpose of acutely reducing ICP. The practical advantages of lower volume may exist but cannot be concluded from our study. The use of 23.5% HTS in isolation may be associated with subsequent decline in serum sodium over the following days and methods to maintain serum sodium should be considered. Thus, the bolus versus infusion debate may best be served via combining both approaches. We suggest that investigation of methods that stabilise ICP with highly hypertonic saline and maintenance with a less hypertonic infusion may be warranted. In this way, volume could be minimised while rapid control of ICP and minimisation of secondary damage may be possible. Further prospective studies are required to guide management of osmotherapy, its constituents and its administration method in paediatric brain injury. 
